Kabi Brings In Reddy’s Rituximab As Biosimilar Breakeven Date Retreats
Indian Firm’s Rituxan Biosimilar Added Amid Pegfilgrastim Frustrations
The Fresenius group had much to say of Fresenius Kabi’s biosimilar business during the firm’s Q4 and year-end results call, which disclosed a US in-licensing deal for Dr Reddy’s proposed rituximab biosimilar and suggested additional biosimilar manufacturing is among its top priorities.
